Beida Pharmaceutical (300558.SZ): Clinical research results of enzalutamide adjuvant therapy after surgery are published.

Intelligence Finance and Economics App News, Beida Pharmaceutical (300558.SZ) announced today that the company's independently developed Ensanibinee hydrochloride capsules (trade name: Beimenar, abbreviated as "Ensanibinee") postoperative adjuvant treatment of IB-IIIB (T3N2M0) stage anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) study (referred to as the "ELEVATE study") was published online in the international authoritative medical journal "New England Journal of Medicine" (impact factor: 84.5). The publication of the ELEVATE study marks the international recognition of the clinical value of Ensanibinee in the field of postoperative adjuvant treatment, providing high-level evidence-based medicine for postoperative adjuvant treatment of NSCLC patients.